Journal Mobile Options
Table of Contents
Vol. 87, No. 1, 2014
Issue release date: January 2014
Respiration 2014;87:63-74

Longitudinal Changes in Clinical Outcomes in Older Patients with Asthma, COPD and Asthma-COPD Overlap Syndrome

Fu J. · Gibson P.G. · Simpson J.L. · McDonald V.M.
aPriority Research Centre for Asthma and Respiratory Diseases, School of Medicine and Public Health, and bSchool of Nursing and Midwifery, Faculty of Health, University of Newcastle, and cHunter Medical Research Institute, Newcastle, N.S.W., dDepartment of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, N.S.W., and eWoolcock Institute of Medical Research, Sydney, N.S.W., Australia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The progression of obstructive airway diseases (OADs) including asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap syndrome in older adults is not well understood. Objective: To examine the prognosis of OADs and to identify potential determinants for longitudinal changes in clinical outcomes. Methods: We consecutively recruited 99 older adults (>55 years) with OADs who underwent a multidimensional assessment at baseline and 4 years which involved spirometry, 6-min walk distance (6MWD), assessments of health status (Saint George's Respiratory Questionnaire, SGRQ), comorbidity, and serum and sputum biomarkers. All-cause mortality and respiratory hospitalisation during the follow-up period were recorded. Clinical outcomes were compared between basal and final visits, and changes in clinical outcomes were compared among asthma, COPD and asthma-COPD overlap groups. Associations between clinical parameters, biomarkers and prognosis were examined. Results: After a median follow-up of 4.2 years, outcome data were available for 75 (75.8%) patients. There were 16 (16.2%) deaths. The BODE index predicted all-cause mortality in older people with OADs. While spirometry, 6MWD and SGRQ deteriorated significantly over the 4 years, there was significant heterogeneity in the longitudinal changes in these clinical outcomes. Participants with COPD had a significant decline in FEV1 (p = 0.003), SGRQ (p = 0.030) and 6MWD [decline of 75.5 (93.4) m, p = 0.024]. The change in 6MWD was lower in the asthma-COPD overlap group. Airflow reversibility was associated with a reduced decline in 6MWD. Conclusion: COPD patients had a poor prognosis compared with asthma and asthma-COPD overlap patients. The BODE index is a useful prognostic indicator in older adults with OADs. Both airway disease diagnosis and BODE index warrant specific attention in clinical practice. © 2013 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Gibson PG, McDonald VM, Marks GB: Asthma in older adults. Lancet 2010;376:803-813.
  2. McDonald VM, Higgins I, Gibson PG: Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges. Drugs Aging 2013;30:1-17.
  3. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. Updated 2012.
  4. Standardization of spirometry - 1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987;136:1285-1298.
  5. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-968.
  6. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2011.
  7. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB: The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003;124:474-481.
  8. Al-Kassimi FA, Abba AA, Al-Hajjaj MS, Alhamad EH, Raddaoui E, Shaikh SA: Asthma masquerading as chronic obstructive pulmonary disease: a study of smokers fulfilling the GOLD definition of chronic obstructive pulmonary disease. Respiration 2011;82:19-27.
  9. Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM, Hansell AL, Nowitz MR, McNaughton AA, Soriano JB, Beasley RW: Proportional classifications of COPD phenotypes. Thorax 2008;63:761-767.
  10. Gibson PG, Simpson JL: The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-735.
  11. Contoli M, Baraldo S, Marku B, Casolari P, Marwick JA, Turato G, Romagnoli M, Caramori G, Saetta M, Fabbri LM, Papi A: Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol 2010;125:830-837.
  12. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo JD, Hersh CP: The clinical features of the overlap between COPD and asthma. Respir Res 2011;12:127.
  13. Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpelainen M, Kinnula VL, Haahtela T, Laitinen T: Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011;48:279-285.
  14. Soler-Cataluna JJ, Cosio B, Izquierdo JL, Lopez-Campos JL, Marin JM, Aguero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, Gonzalez MC, Miravitlles M, Monso E, Montemayor T, Morera J, Ortega F, Peces-Barba G, Puente L, Rodriguez JM, Sala E, Sauleda J, Soriano JB, Viejo JL: Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48:331-337.
  15. Kim TB, Oh YM, Chang YS, Cho YS, Jang AS, Cho SH, Choi BW, Lee SD, Moon HB: The reality of an intermediate type between asthma and COPD in practice. Respir Care 2012;57:1248-1253.
  16. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
  17. McDonald VM, Simpson JL, Higgins I, Gibson PG: Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing 2010;40:42-49.
  18. Dreborg S: Bronchial hyper-reactivity and skin sensitivity. Clin Exp Allergy 1991;21:529.
  19. Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, Cripps AW, Clancy RL: Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med 1998;158:36-41.
  20. Sato S, Nishimura K, Koyama H, Tsukino M, Oga T, Hajiro T, Mishima M: Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. Chest 2003;124:1749-1754.
  21. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.
  22. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
  23. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
  24. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B: The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis 1976;113:587-600.

    External Resources

  25. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
  26. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI: Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-1192.
  27. Anthonisen NR, Wright EC, Hodgkin JE: Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20.

    External Resources

  28. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC: Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003;58:388-393.
  29. Berry CE, Wise RA: Mortality in COPD: causes, risk factors, and prevention. COPD 2010;7:375-382.
  30. Oga T, Tsukino M, Hajiro T, Ikeda A, Koyama H, Mishima M, Chin K, Nishimura K: Multidimensional analyses of long-term clinical courses of asthma and chronic obstructive pulmonary disease. Allergol Int 2010;59:257-265.
  31. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Koyama H, Mishima M: Longitudinal changes in patient vs. physician-based outcome measures did not significantly correlate in asthma. J Clin Epidemiol 2005;58:532-539.
  32. Oga T, Nishimura K, Tsukino M, Hajiro T, Sato S, Ikeda A, Hamadas C, Mishima M: Longitudinal changes in health status using the chronic respiratory disease questionnaire and pulmonary function in patients with stable chronic obstructive pulmonary disease. Qual Life Res 2004;13:1109-1116.
  33. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M: Exercise capacity deterioration in patients with COPD: longitudinal evaluation over 5 years. Chest 2005;128:62-69.
  34. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW: Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-664.
  35. Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE, Lung Health Study Research Group: Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005;26:45-51.
  36. Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS: Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003;58:322-327.
  37. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, Igarashi T, Akiyama Y, Ogura S: Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52.
  38. Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA: Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1301-1306.
  39. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-338.
  40. Casanova C, de Torres JP, Aguirre-Jaime A, Pinto-Plata V, Marin JM, Cordoba E, Baz R, Cote C, Celli BR: The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2011;184:1015-1021.
  41. Casanova C, Cote CG, Marin JM, de Torres JP, Aguirre-Jaime A, Mendez R, Dordelly L, Celli BR: The 6-min walking distance: long-term follow up in patients with COPD. Eur Respir J 2007;29:535-540.
  42. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF: Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2010;91:221-225.
  43. Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, Wise RA, Sciurba F: The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011;37:784-790.
  44. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH: Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278-1282.
  45. Jones PW: St. George's Respiratory Questionnaire: MCID. COPD 2005;2:75-79.
  46. Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B, Mistry V, Reid C, Parker D, Dodson P, Jenkins M, Lloyd A, Rugman P, Newbold P, Brightling CE: Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 2012;83:36-44.
  47. Kroegel C, Bakakos P: The inflammatory effector cell pattern in asthma and chronic obstructive pulmonary disease - what is it good for? Respiration 2012;83:17-19.
  48. Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B, DiMaria G, Foresi A, Hargreave FE, Holgate ST, Inman M, Lotvall J, Magnussen H, Polosa R, Postma DS, Riedler J: Indirect airway challenges. Eur Respir J 2003;21:1050-1068.
  49. Van Schoor J, Pauwels R, Joos G: Indirect bronchial hyper-responsiveness: the coming of age of a specific group of bronchial challenges. Clin Exp Allergy 2005;35:250-261.
  50. Cockcroft D, Davis B: Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol 2009;103:363-369, quiz 369-372, 400.
  51. Silva GE, Sherrill DL, Guerra S, Barbee RA: Asthma as a risk factor for COPD in a longitudinal study. Chest 2004;126:59-65.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50